Occudo Quantitative Strategies LP Makes New Investment in Zoetis Inc. (NYSE:ZTS)

Occudo Quantitative Strategies LP bought a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 6,575 shares of the company's stock, valued at approximately $1,071,000.

Other large investors have also recently made changes to their positions in the company. Callahan Advisors LLC raised its holdings in shares of Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after acquiring an additional 6,221 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after acquiring an additional 46,050 shares in the last quarter. Schroder Investment Management Group raised its holdings in Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after purchasing an additional 6,169 shares in the last quarter. Vanguard Group Inc. raised its holdings in Zoetis by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock worth $6,739,905,000 after purchasing an additional 120,158 shares in the last quarter. Finally, Alberta Investment Management Corp raised its holdings in Zoetis by 2,050.0% in the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company's stock worth $4,904,000 after purchasing an additional 28,700 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

NYSE ZTS traded up $2.68 during trading hours on Friday, reaching $163.03. The stock had a trading volume of 2,391,686 shares, compared to its average volume of 2,513,944. The stock has a fifty day moving average of $156.46 and a 200 day moving average of $165.43. The stock has a market cap of $72.58 billion, a P/E ratio of 29.80, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 earnings per share. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Insider Activity at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. UBS Group dropped their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Finally, Stifel Nicolaus dropped their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.